Brain Safe App for Alzheimer's Disease
Trial Summary
What is the purpose of this trial?
This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.
Research Team
Richard J Holden, PhD
Principal Investigator
Indiana University School of Medicine
Eligibility Criteria
This trial is for adults over 60 in Central Indiana who are English-speaking, have had a primary care visit within the last year, and are currently prescribed strong anticholinergic medications. They must not be cognitively impaired, terminally ill, or living in extended care facilities. Those with Alzheimer's disease or severe mental health conditions like schizophrenia cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Attention Control App
- Brain Safe App
Find a Clinic Near You
Who Is Running the Clinical Trial?
Indiana University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator